
DVLP Medicines
Creating a software co-pilot for drug development and a new marketplace for investors and outsourced R&D and manufacturing
Moleculo’s founders developed new library prep and analysis techniques that allowed them to assemble short sequences of DNA base-pair information into accurate, synthetic long reads. Illumina acquired the company in 2013.
Creating a software co-pilot for drug development and a new marketplace for investors and outsourced R&D and manufacturing
Using self-supervised machine learning to map the circuit diagram of tumor biology and develop new immunotherapies for cancer
Advancing precision medicine by combining the efficacy of antibodies with the binding ability of small molecules
Using synthetic biology to manufacture carbon-negative materials